Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
Fda released a safety communication on january 21 2015 regarding the use of bone graft substitutes containing recombinant proteins or synthetic peptides in patients under age 18. in response to this communication the warning for the pepgen products will be updated to include a statement indicating product is not for use in patients under the age of 18.